AI Impact on Monoclonal Antibodies in Oncology Market - Pulse Report

Artificial intelligence (AI) is massively transforming the global monoclonal antibodies (mAbs) in oncology market by accelerating and de-risking the development pipeline. Deep learning (DL) and generative models enable rapid screening of molecular libraries, identifying and designing novel antibody sequences with optimized properties for drug safety and efficacy. This in silico precision reduces reliance on traditional experimental methods, reducing development time and cost. AI is also increasingly used for predictive modeling to assess an antibody’s developability and to personalize cancer treatment by predicting a patient’s response to specific mAb therapies.

Major companies operating within the monoclonal antibodies in oncology industry, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co., and AstraZeneca, are at the forefront of AI integration in R&D and drug manufacturing.

This report provides a global outlook of the AI impact on monoclonal antibodies in oncology. It also highlights major AI adoption and disruption trends across the regions.

The report includes:

• Impact analysis of artificial intelligence on the global monoclonal antibodies in oncology market
• Insights of the use cases/case studies for AI implementation related to monoclonal antibodies in oncology
• Understanding of AI adoption trends across the major geographic regions
• Review of AI disruption trends across the key industry verticals
• Impact of AI on various stages of the value chain
• Analysis of the companies’ market spendings and forecasting analysis, and a VC investment outlook